Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript
Okay. Let's go ahead and get started. So welcome, everyone, to the first day afternoon session of the 41st Annual J.P. Morgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Priyanka Grover and Malcolm Kuno from the team. Our next presenting company is Kiniksa, and presenting on behalf of the company, we have CEO, Sanj Patel. Sanj?
Thanks, Anupam. Thank you to JPMorgan for hosting us today. It's been a wee while since we have done these types of presentations in person. So it's great to see all of you again here today. Kiniksa has a pipeline of assets that have the potential to help patients that have a range of cardiovascular and autoimmune diseases. We are well positioned for both near- and long-term growth, and I'm really excited to give you an overview of the company today.
First, please note that I will be making forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |